Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep Ltd ( (AU:IMM) ) has issued an announcement.
Immutep Ltd has announced a change in the interest of its director, Dr. Frederic Triebel, involving the conversion of 900,000 performance rights into fully paid ordinary shares. This adjustment, which was previously approved by shareholders, reflects the company’s ongoing commitment to aligning executive incentives with shareholder interests, potentially impacting its market perception and stakeholder confidence.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments, primarily targeting cancer and autoimmune diseases. The company is known for its innovative approach in leveraging the LAG-3 immune control mechanism to enhance the body’s immune response against tumors.
Average Trading Volume: 2,480,709
Technical Sentiment Signal: Hold
Current Market Cap: A$426.9M
Learn more about IMM stock on TipRanks’ Stock Analysis page.